Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Overall survival ‐ first‐line studies · women with advanced or recurrent endometrial cancer

mTOR inhibitors showed no clear difference in overall survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
HR 1.32 [0.98, 1.78]
1 study · 231 participants
Low

Overall survival · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy

EGFR tyrosine kinase inhibitor (TKI) showed no clear difference in overall survival compared with observation alone (low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
HR 0.99 [0.81, 1.2]
1 study · 835 participants
Low